<DOC>
	<DOCNO>NCT02888106</DOCNO>
	<brief_summary>Randomised , Comparative , Parallel-Arm Study Assess Efficacy Safety Myrcludex B Combination Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone Patients Chronic Viral Hepatitis B Delta-agent</brief_summary>
	<brief_title>Myrcludex B Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone Patients With Chronic Viral Hepatitis B With Delta-agent</brief_title>
	<detailed_description>This multicenter , open-label , randomise , comparative , active-controlled parallel-arm phase II study . The study conduct Russia . The aim study investigate efficacy safety Myrcludex B alone combination peginterferon alfa-2a compare peginterferon alfa-2a alone patient chronic viral hepatitis B delta-agent . The study also aim investigate immunogenicity Myrcludex B drug pharmacokinetics use combination PEG IFN alfa-2a . It plan screen 100 patient , 60 patient randomise four treatment arm 1:1:1:1 ratio . - Arm A ( n=15 ) : PEG IFN alfa-2a 180 µg 48 week - Arm B ( n=15 ) : Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg 48 week - Arm C ( n=15 ) : Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg 48 week - Arm D ( n=15 ) : Myrcludex B 2 mg 48 week</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1 . Signed Informed Consent form . 2 . Males females 18 65 year age ( inclusively ) . 3 . Patients chronic hepatitis B ( HBeAgpositive negative ) HBsAgpositive least 6 month prior Screening . 4 . Positive antiHDV antibody least 6 month prior Screening . 5 . HDV RNApositive Screening . 6 . ALT ≥ 1 x ULN &lt; 10 x ULN . 7 . The patient agree use adequate method contraception study , start time Informed Consent sign completion Followup Period . 1 . Intolerance hypersensitivity active ingredient component study drug Myrcludex B . 2 . Intolerance hypersensitivity interferon alfa , genetically engineer E.coli medication , polyethylene glycol component peginterferon alfa2a . 3 . Previous treatment Myrcludex B ( patient previous exposure interferon eligible ) . 4 . Therapy antiviral drug chronic viral hepatitis B deltaagent previous 6 month . 5 . Therapy antitumour agent ( include radiotherapy ) immunomodulatory medication ( include systemic glucocorticoid ) previous 6 month . 6 . The following laboratory test result Screening : 1 . Hemoglobin &lt; 100 g/L 2 . Leucocytes &lt; 3000/µL 3 . Neutrophils &lt; 1500/µL 4 . Platelets &lt; 90000/µL 5 . Serum creatinine &gt; 1.5 x ULN . 7 . Total bilirubin &gt; 34.2 µM/L . Patients higher total bilirubin may enrol upon consultation study Medical Monitor , clear evidence elevate bilirubin cause Gilbert 's syndrome . 8 . Current previous decompensated liver disease , include coagulopathy , hyperbilirubinemia , hepatic encephalopathy , hypoalbuminaemia , ascites , oesophageal varix haemorrhage ; ChildPugh score B/C ≥6 point . 9 . HCV HIV coinfection ( patient antiHCV antibody HCV RNA Screening eligible ) . 10 . Hepatocellular carcinoma . 11 . Signs drug alcoholinduced liver disease medical condition associate chronic liver disease ( e.g . autoimmune hepatitis , hemochromatosis , thalassaemia , alcoholic hepatitis , toxic liver disease ) . 12 . Contraindications liver biopsy . 13 . Concurrent malignancy ( current diagnose suspected malignancy ; risk previous malignancy recurrence ) . 14 . Severe decompensated cardiovascular disease , include unstable poorly control condition , 6 month Screening . 15 . History poorly control thyroid condition clinically significant sign thyroid dysfunction Screening . 16 . Previous current severe renal failure significant renal dysfunction Screening . 17 . Previous current chronic pulmonary disease respiratory distortion Screening . 18 . Previous current severe retinopathy , significant ophthalmology disorder associate diabetes mellitus hypertension . 19 . Previous current severe psychiatric disorder Screening ( e.g . severe depression , suicidal attempt , severe neurosis cognitive disorder ) . 20 . Previous current endocrine disorder ( hypoglycaemia , hyperglycaemia , diabetes mellitus ) adequately control Screening . 21 . History visceral organ transplantation . 22 . Signs drug and/or alcohol dependence ( 80 g alcohol/day men 40 g alcohol/day woman ) within 1 year Screening . 23 . History immune disorder ( e.g . idiopathic thrombocytopenic purpura , lupus erythematosus , sclerodermia , severe psoriasis , rheumatoid arthritis ) . 24 . Need concomitant use glucocorticoid myelotoxic agent . 25 . Participation another clinical study within 30 day prior enrollment study . 26 . Pregnant breastfeeding female . 27 . Any condition , opinion Investigator , preclude patient take part study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>